**FasL −844T/C and Fas −1377G/A: mutations of pulmonary adenocarcinoma in South China and their clinical significances**

**Abstract** Apoptosis is an important mechanism of malignant tumor formation and progression. Single nucleotide polymorphisms (SNPs) located within cell death genes may influence cancer risk. We explored the relationship between FasL −844T/C and/or Fas −1377G/A SNPs and pulmonary adenocarcinoma (AD). Two hundred seventy-five patients with pulmonary AD of South China admitted into Zhejiang Cancer Hospital from July 2007 to October 2011 were randomly selected, and their clinicopathological data were collected at the same time. Two hundred ninety-seven cases of healthy individuals were selected as control. FasL −844T/C and Fas −1377G/A SNPs were detected by PCR-RFLP technique to evaluate the relationships between these two SNPs and pulmonary AD. Age, FasL −844 and Fas −1377 SNPs were associated with increased risk of pulmonary AD susceptibility in main effect analysis. FasL −844CC and Fas −1377 AA were associated with an increased risk for the development of pulmonary AD only in age <60 years people, but not in those ≥60 years. FasL −844CC genotype was associated with an increased risk for pulmonary AD (adjusted OR=2.010, 95% CI 1.196–3.379, \( P=0.008 \)) compared with TT genotype. However, Fas −1377 AA was a risk factor only when FasL −844 genotype was CC. Fas −1377 genotypes showed significant effect modification of pulmonary AD risk by FasL −844 genotype with test of the interaction term adjusting for age, gender, and FasL −844 SNP. Fas −1377G/A was not associated with the clinicopathological factors, while FasL −844C/T was associated with tumor stage and lymph node metastasis in age ≥60 years people and tumor stage in those <60 years. In conclusion, FasL −844 SNP is associated with the susceptibility of pulmonary AD in age <60 years people. Fas −1377 SNP may modify the association of FasL −844 SNP with the risk of pulmonary AD. FasL −844 genotype plays an important role in the occurrence and progression of pulmonary AD.

**Keywords** FasL · Fas · SNP · Pulmonary adenocarcinoma

**Introduction**

Lung cancer is the most common primary malignancy and the leading cause of cancer-related deaths worldwide [1]. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Adenocarcinoma (AD) accounts for 50% of NSCLC cases. It is one of the most frequent histologic subtypes and presently the most common type in most countries. Since 30–40 years ago, the incidence of AD has increased steadily [2, 3].

Approximately 80–90% of lung carcinomas are associated with the carcinogenic effect of smoking [4]. However, only about 10–15% of all smokers fall ill on lung cancer. On the other side, 10–15% of all lung carcinomas occur in non-smokers [5]. These facts indicate that there is individual susceptibility to lung carcinogens as well as to development of disorders. Genetic and environmental factors essentially influence the risk of lung cancer genesis, while molecular
Acquired ability to resist apoptosis is a common hallmark of various types of malignant diseases, and the regulatory defects of components of the apoptosis pathway contribute to tumorigenesis, tumor cell invasion, and metastasis [6, 7]. Genetic variations of crucial genes in this cell-death pathway may thus influence the susceptibility to cancer. The Fas−Fas ligand (FasL) system is recognized as a major pathway for the induction of apoptosis in cells and tissues [8]. Fas interacts with FASL to initiate the death signal cascade and activate the apoptotic signal transduction have been shown to be associated with tumorigenesis, tumor cell invasion, and metastasis [6, 7]. Fas/FasL system may be significant in cancer initiation, development, and progression, and SNPs, which possess the potential to alter the expression of Fas and/or FasL, have been proposed to play an important role in the genetic susceptibility to cancer [9]. Decreased expression of Fas and/or increased expression of FasL is associated with different malignancies and may favor malignant transformation and progression [10].

Single nucleotide polymorphisms (SNPs) have been proposed to play an important role in the genetic susceptibility to cancer. Many gene SNPs can impact the risk of cancer. The functional mutations in the Fas/FasL genes that impair apoptotic signal transduction have been shown to be associated with an increased risk of many types of cancers [11–15]. The Fas/FasL system may be significant in cancer initiation, development, and progression, and SNPs, which possess the potential to alter the expression of Fas and/or FasL, have been proposed to be significant in the genetic susceptibility to cancer.

We have studied the clinical significances of FasL −844T/C and Fas −1377G/A mutation in esophageal carcinoma [16]. Now, we want to analyze whether FasL −844T/C and Fas −1377G/A polymorphism influence the susceptibility or clinicopathological factor of pulmonary AD.

### Materials and methods

#### Subjects

Patients with histopathologically confirmed pulmonary AD (n=275) were recruited from Zhejiang Cancer Hospital, affiliated hospital of Zhejiang Medical College, China, between July 2007 and October 2011. Control subjects (n=297) were cancer-free individuals who had been randomly selected from medical examination center. All subjects were unrelated ethnic Han Chinese and residents in South China. There was no sex and age restriction. Before recruitment, a standard questionnaire had been administered through face-to-face interviews by trained interviewers to obtain information on demographic data and related factors. At recruitment, written informed consent was obtained from each subject to consent to participate in the study and to allow their biological samples to be genetically analyzed. This research was approved by the Medical Ethics Committee, Zhejiang Cancer Hospital.

All patients underwent radical resection and had detailed clinicopathological data. The tumor staging was determined according to UICC 2009 7th Edition. The presence or absence of lymph node metastasis was evaluated according to the tumor node metastasis classification on the basis of postoperative histopathologic examination of pulmonary AD specimens. Other clinical data (age at diagnosis, sex, tumor length) and tumor biological data (grading, visceral pleura, vascular tumor thrombus) were also documented.

#### Table 1  Baseline clinical characteristics and the genotypic and allelic frequencies of SNPs of cases and controls

| Variable         | Cases (%) | Controls (%) | χ²  | P value |
|------------------|-----------|--------------|-----|---------|
| Gender           |           |              |     |         |
| male             | 147       | 179          | 2.705 | 0.100  |
| female           | 128       | 118          |     |         |
| Age              |           |              |     |         |
| <60              | 119       | 192          | 26.293 | 0.000** |
| ≥60              | 156       | 105          |     |         |
| Smoking status   |           |              |     |         |
| no               | 219       | 254          | 0.062 | 0.803  |
| yes              | 56        | 63           |     |         |
| FasL −844 Genotypes |         |              |     |         |
| TT               | 32        | 52           | 8.692 | 0.013*  |
| TC               | 103       | 128          |     |         |
| CC               | 140       | 117          |     |         |
| Alleles          |           |              |     |         |
| T allele         | 167       | 232          | 9.503 | 0.002** |
| C allele         | 383       | 362          |     |         |
| Fas −1377 Genotypes |         |              |     |         |
| GG               | 89        | 121          | 6.605 | 0.037*  |
| GA               | 133       | 138          |     |         |
| AA               | 53        | 38           |     |         |
| Alleles          |           |              |     |         |
| G allele         | 311       | 380          | 6.587 | 0.010*  |
| A allele         | 239       | 214          |     |         |

*P<0.05; **P<0.01

#### Table 2  Main effects of individual risk factors on pulmonary AD risk by Logistic regression

| Variable         | Crude OR (95 % CI) | P value | Adjusted OR (95 % CI) | P value |
|------------------|--------------------|---------|-----------------------|---------|
| Age              | 2.397 (1.712–3.357) | 0.000   | 2.610 (1.815–3.754)  | 0.000   |
| FasL −844 844 locus | 1.418 (1.211–1.794) | 0.004   | 1.418 (1.111–1.811)  | 0.005   |
| Fas −1377 1377 locus | 1.363 (1.074–1.730) | 0.011   | 1.364 (1.065–1.746)  | 0.014   |

* Adjusting for gender, smoking status, FasL −844, and Fas −1377 SNP

** Adjusting for age, gender, smoking status, and Fas −1377 SNP

* Adjusting for age, gender, smoking status, and FasL −844 SNP
Genotyping

After signing informed consent forms, each subject donated 3 mL of blood to be used for genomic DNA extraction. Genomic DNA was extracted from peripheral blood using Blood Genome DNA Extraction Kit (Takara Biotechnology Co. Ltd., Dalian). The $-844T/C$ polymorphism of FasL was detected using PCR-RFLP. DNA fragments were amplified in a total volume of 100 μL PCRs containing PCR Premix 50 μL (BioTeke Corporation, Beijing, China), forward primer (5′-CAGCTACTCGGAGGCCAAG-3′) 1 μL, reverse primer (5′-GCTCTGAGGGGAGAGACCAT-3′) 1 μL, DDW 46 μL, and DNA 2 μL. Amplification was carried out under the following condition: 1 cycle of 2 min at 95 °C, 35 cycles of 30 s at 94 °C, 30 s at 62 °C, and 45 s at 72 °C, followed by 7 min at 72 °C. Amplified products were digested with BsrDI (Fermentas, Thermo Fisher Scientific Inc.) at 55 °C for 4 h. All products were loaded onto 3% MS-6 Agarose (Takara Biotechnology Co. Ltd., Dalian) and electrophoresed. Bands were visualized and typed after GelRed (Biotium Company, USA) staining. The PCR product amplified for the polymorphism was 410 bp. The BsrDI restriction enzymes were used to distinguish $-844T/C$, resulting in 122- and 104-bp fragments in the presence of the $-844T$ allele.

Fas $-1377G/A$ polymorphism in promoter region was also detected with PCR-RFLP. The primers for amplification were 5′-TGTGTGCACAAGGCTGGCGC-3′ for forward primer and 5′-TGCATCTGTCACTGCACTTACCACCA-3′ for reverse primer, which produce 122-bp fragment. To introduce a restriction endonuclease site, 3′ end of forward primer was changed from CAC to CGC, which created a BstUI site. The procedure of amplification was the same as above. After PCR, BstUI (New England Biolabs, USA) digestion generated fragments of 104 and 18 bp for G allele.

The polymorphism analysis was performed by two persons independently in a blind fashion. More than 10% of the

Table 3  Association of genotypic and allelic frequencies of FasL $-844$ and Fas $-1377$ with pulmonary AD risk

| Locus  | Genotypes | Crude OR (95 % CI) | $P$ value | Adjusted OR* (95 % CI) | $P$ value |
|--------|------------|--------------------|-----------|------------------------|-----------|
| FasL $-844$ Genotypes | | | | | |
| TT | 1 | 1 |
| TC | 1.308 (0.784–2.180) | 0.304 | 1.300 (0.769–2.198) | 0.328 |
| CC | 1.944 (1.174–3.219) | 0.010* | 2.010 (1.196–3.379) | 0.008** |
| Alleles | | | | | |
| $T$ allele | 1 | 1 |
| $C$ allele | 1.470 (1.150–1.7879) | 0.002** | 1.504 (1.169–1.936) | 0.002** |
| Fas $-1377$ Genotypes | | | | | |
| GG | 1 | 1 |
| GA | 1.310 (0.912–1.883) | 0.144 | 1.252 (0.860–1.823) | 0.241 |
| AA | 1.377 (1.073–1.767) | 0.012* | 1.400 (1.083–1.809) | 0.010* |
| Alleles | | | | | |
| $G$ allele | 1 | 1 |
| $A$ allele | 1.233 (0.938–1.620) | 0.133 | 1.242 (0.937–1.646) | 0.132 |

*P<0.05; **P<0.01

* Adjusting for age and gender

Table 4  Risk of pulmonary AD associated with FasL $-844$ genotypes by Fas $-1377$ genotypes

| FasL $-844$ | Fas $-1377$ | Cases (%) ($n=275$) | Controls (%) ($n=297$) | Crude OR (95 % CI) | $P$ value | Adjusted OR* (95 % CI) | $P$ value |
|-------------|-------------|----------------------|-------------------------|--------------------|-----------|------------------------|-----------|
| TT + TC     | GG + GA     | 113                  | 156                     | 1                  | 1         | 1                      | 1         |
| TT + TC     | AA          | 22                   | 24                      | 1.265 (0.676–2.369) | 0.462     | 1.442 (0.750–2.774)    | 0.273     |
| CC          | GG + GA     | 109                  | 103                     | 1.209 (1.009–1.449) | 0.04      | 1.228 (1.016–1.484)    | 0.033     |
| CC          | AA          | 31                   | 14                      | 1.451 (1.159–1.818) | 0.01      | 1.519 (1.201–1.922)    | 0.000     |
| CC          | GG + GA     | 109                  | 103                     | 1                  | 1         | 2.092 (1.054–4.156)    | 0.035     |
| CC          | AA          | 31                   | 14                      |                    |           | 2.108 (1.025–4.337)    | 0.043     |

* Adjusting for age and gender
samples were randomly selected for confirmation, and the results were 100% concordant.

Statistical analyses

Values were expressed as mean±SD or percent. To check for genotyping error, we examined departure from Hardy–Weinberg equilibrium (HWE) in controls, using χ² test. χ² test analysis was used to detect these SNPs in patients with pulmonary AD and health individuals. The t test and χ² test were used to detect age and sex in the two groups, respectively.

Association between FasL −844T/C or Fas −1377G/A polymorphism and pulmonary AD was assessed using χ² test. Pulmonary AD risk was estimated by odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression or multinomial logistic regression controlling for age and gender. This codominant model was defined as heterozygotes (1 variant genotype) versus wild-type (0 variant genotype) or homozygotes (2 variant genotype) versus wild-type.

The relationships of these SNPs with the clinicopathological parameters of patients were analyzed by χ² test. We used binary logistic regression (Ascendant Wald method) with each parameter as dependent variable and genotypes of FasL −844T/C or Fas −1377G/A polymorphism as independent variables. Clinicopathological parameters were dichotomized as follows: grading (well and moderately differentiation versus poorly differentiation), stage (stage I versus stages II–IIIa), tumor length (less than and equal to 3 cm versus greater than 3 cm), visceral pleura, lymph node metastasis, and vascular tumor thrombus (positive versus negative).

For stratified analyses, we created indicator variable of age greater or less than 60 years old. Then, the above statistical analyses were carried out at different age groups.

All statistical testing was done at the two-sided 0.05 level with SPSS 16.0 software.

Results

Gene polymorphisms and the association with pulmonary AD

This population-based case-control study included 275 patients with pulmonary AD and 297 control subjects. All study subjects were south Chinese. Baseline clinical characteristics, the genotype, and allele distributions of FasL and Fas polymorphisms in cases and controls are summarized in Table 1.

Cases were older than controls (P=0.000). The FasL −844T/C and Fas −1377G/A genotype frequencies were all in agreement with Hardy–Weinberg equilibrium in the
controls (χ²=2.663, P=0.103; χ²=0.019, P=0.890, respectively).

Age, FasL −844, and Fas −1377 SNPs were associated with increased risk of pulmonary AD susceptibility in main effect analysis (Table 2).

Effect modification of the associations of the SNP
with pulmonary AD

Logistic regression analysis was used to estimate associations between the genotypes and risk of pulmonary AD (Table 3). Adjusting for age and gender, FasL −844CC genotype was associated with an increased risk for pulmonary AD (aOR=2.010, 95 % CI=1.196–3.379, P=0.008) compared with TT genotype. The C haplotype remained a significant risk for pulmonary AD (aOR=1.504, 95 % CI=1.169–1.936, P=0.002), compared with T haplotype. Fas −1377 AA genotype was also associated with an increased risk for pulmonary AD (aOR=1.400, 95 % CI 1.083–1.809, P=0.010) compared with GG genotype.

Risk of pulmonary AD was evaluated by combining FasL −844 genotypes and Fas −1377 genotypes (Table 4). FasL −844CC was still a risk factor for pulmonary AD no matter what Fas −1377 genotypes was. However, Fas −1377 AA was not a risk factor for pulmonary AD when FasL −844 genotype was TT and TC but was a risk factor when FasL −844 genotype was CC.

Fas −1377 genotypes showed significant effect modification of pulmonary AD risk by FasL −844 genotype by test of the interaction term adjusting for age, gender, FasL −844, and Fas −1377 SNP (aOR=1.531, 95 % CI=1.066–2.201, P=0.021).

The relationships between clinicopathological significance and the polymorphisms

The relationships between pulmonary AD clinicopathological parameters and these two SNPs were compared (Table 5). There were no significant differences between Fas −1377 gene polymorphism and tumor size, differentiation visceral pleura, stage, lymph node metastasis, and vascular tumor thrombus, while FasL −844C/T was associated with tumor stage and lymph node metastasis. CC versus TT was dangerous, aOR=2.273 (1.436–3.599), P=0.000; aOR=2.053 (1.297–3.249), and P=0.002, respectively (Table 6).

| Locus  | Genotypes | Stage | Adjusted OR# (95 % CI) | P  |
|--------|------------|-------|------------------------|----|
| FasL −844 | TT         | 1     | 1                      |    |
|         | TC         | 2.573 (1.003–6.601) | 0.049* |
|         | CC         | 2.273 (1.436–3.599) | 0.000**|

*P<0.05; **P<0.01
# Adjusting for age and gender

| Number (%) | Age | Smoking status | Gender | FasL −844 genotypes | Fas −1377 genotypes |
|------------|-----|----------------|--------|---------------------|--------------------|
|            |     |                |        | TT                  | CC                |
|            |     |                |        | TC                  | GG                |
|            |     |                |        | GC                  | GA                |
|            |     |                |        | CC                  | AA                |
|            | <60 | No             | Male   | 109 (91.6)          | 62 (52.1)         |
|            |     | Yes            | Female | 10 (8.4)            | 57 (47.9)         |
|            |     |                |        | 12 (10.1)           | 43 (36.1)         |
|            |     |                |        | 45 (36.1)           | 64 (53.8)         |
|            |     |                |        | 35 (18.3)           | 83 (43.2)         |
|            |     |                |        | 78 (40.6)           | 74 (38.5)         |
|            |     |                |        | 78 (40.6)           | 78 (40.6)         |
|            |     |                |        | 88 (45.8)           | 26 (13.5)         |
|            | ≥60 | No             | Male   | 110 (70.5)          | 85 (54.5)         |
|            |     | Yes            | Female | 46 (29.5)           | 71 (45.5)         |
|            |     |                |        | 20 (12.8)           | 60 (38.5)         |
|            |     |                |        | 60 (38.5)           | 76 (48.7)         |
|            |     |                |        | 76 (48.7)           | 48 (30.8)         |
|            |     |                |        | 85 (54.5)           | 23 (14.7)         |
|            |     |                |        | 43 (41.0)           | 43 (41.0)         |
|            |     |                |        | 43 (41.0)           | 50 (47.6)         |
|            |     |                |        | 26 (13.5)           | 12 (11.4)         |
|            |     |                |        | 71 (45.5)           | 43 (41.0)         |
|            |     |                |        | 40 (38.1)           | 45 (42.9)         |
|            |     |                |        | 45 (42.9)           | 43 (41.0)         |
|            |     |                |        | 78 (40.6)           | 78 (40.6)         |
|            |     |                |        | 88 (45.8)           | 26 (13.5)         |
|            |     |                |        | 26 (13.5)           | 12 (11.4)         |

*P<0.05; **P<0.01

Table 6 Risk of pulmonary adenocarcinoma stage and lymph node metastasis according to FasL −844 genotypes

Table 7 Genotypic and allelic frequencies of FasL −844 and Fas −1377 in subgroups according to age
Patients with pulmonary AD and healthy group were stratified by age to explore whether FasL $-844T/C$ and Fas $-1377G/A$ polymorphisms were associated with pulmonary AD in this selected population of patients (Table 7). The two genotype frequencies in two control subgroups (<60 and ≥60 years old) agreed with frequencies expected under the Hardy-Weinberg equilibrium ($\chi^2 = 1.852$, $P = 0.174$ and $\chi^2 = 0.792$, $P = 0.373$ for FasL $-844C/T$; $\chi^2 = 0.022$, $P = 0.881$ and $\chi^2 = 0.197$, $P = 0.657$ for Fas $-1377G/A$, respectively).

With age <60 years, the frequencies of the TT, TC, and CC of FasL $-844$ genotypes were 10.1, 36.1, and 53.8 %, respectively, among the cases and 18.2, 43.2, and 38.5 %, respectively, among the controls, which had statistical difference ($\chi^2 = 7.983$, $P = 0.018$). The genotype frequencies of Fas $-1377$ also had statistical difference ($\chi^2 = 6.794$, $P = 0.033$). In main effect analysis, FasL $-844$ and Fas $-1377$ SNPs in <60 subgroups were associated with increased risk of pulmonary AD susceptibility (Table 8).

For those over age 60, there were no differences between the two groups about genotypes or alleles.

We conducted further analyses to explore whether FasL $-844T/C$ polymorphism was associated with clinicopathological parameters in the selected population of patients (Table 9). For those <60 years, FasL $-844T/C$ showed significant association with tumor stage (crude OR = 1.974, 95 % CI 1.113–3.502, $P = 0.020$; aOR by smoking and sex = 1.995, 95 % CI = 1.098–3.502, $P = 0.023$). For those ≥60 years, FasL $-844T/C$ showed significant associations with stage (crude OR = 2.119, 95 % CI 1.301–3.451, $P = 0.003$; adjust OR by smoking and sex = 2.228, 95 % CI 1.351–3.675, $P = 0.002$) and lymph node metastasis (crude OR = 2.051, 95 % CI 1.252–3.361, $P = 0.004$; adjust OR by smoking and sex = 2.123, 95 % CI = 1.285–3.508, $P = 0.003$).

### Discussion

Fas–FasL system plays an important role in regulating apoptosis and maintaining cellular homeostasis. FasL is an important gene in lung AD. Nineteen genes were designated as candidate lung tumor progression (LTP) genes because their expression changes may specially affect lung tumor progression in mice. FasL was the most important gene among these LTP genes [17].

Fas and FasL genes are located on chromosomes 10q24.1 and 1q23, respectively. Fas $-1377$ polymorphism is in tight linkage disequilibrium with FAS $-670$ polymorphisms. Fas $-1377A$ allele disrupts Sp1 transcription factor binding sites, and FAS $-670G$ allele abolishes STAT1-binding sites, both of which diminish Fas promoter activity and decrease gene expression [11]. FasL $-844T/C$ polymorphism is located in the

#### Table 8 Main effects of individual risk factors on pulmonary adenocarcinoma risk by Logistic regression in age <60 years group

| Variable       | Crude OR (95 % CI) | $P$ value | Adjusted OR (95 % CI) | $P$ value |
|----------------|--------------------|-----------|-----------------------|-----------|
| FasL $-844$    | 1.612 (1.151–2.256) | 0.005     | 1.642 (1.167–2.310)*   | 0.004     |
| Fas $-1377$    | 1.408 (1.024–1.936) | 0.035     | 1.411 (1.020–1.951)*   | 0.038     |

* Adjusting for gender, smoking and Fas $-1377$ locus

#### Table 9 Distribution of selected characteristics of patient subgroup cohort

|        | <60 |        | ≥60 |        |
|--------|-----|--------|-----|--------|
|        | FasL $-844$ | Fas $-1377$ | FasL $-844$ | Fas $-1377$ |
|        | $\chi^2$ | $P$ | $\chi^2$ | $P$ | $\chi^2$ | $P$ | $\chi^2$ | $P$ |
| Smoking | 1.495 | 0.473 | 4.046 | 0.132 | 1.615 | 0.446 | 0.825 | 0.662 |
| Gender  | 1.265 | 0.531 | 0.031 | 0.985 | 1.206 | 0.574 | 0.782 | 0.677 |
| Tumor length | 2.064 | 0.356 | 0.477 | 0.788 | 0.623 | 0.732 | 0.207 | 0.122 |
| Differentiation | 1.848 | 0.397 | 0.174 | 0.917 | 0.477 | 0.788 | 2.094 | 0.351 |
| Visceral pleura | 0.13 | 0.931 | 0.609 | 0.738 | 0.797 | 0.671 | 0.442 | 0.802 |
| Stage  | 6.471 | 0.039* | 2.069 | 0.355 | 9.594 | 0.008* | 0.073 | 0.964 |
| Lymph node metastasis | 4.152 | 0.125 | 0.848 | 0.654 | 8.823 | 0.012* | 0.001 | 1.000 |
| Vascular tumor thrombus | 3.588 | 0.166 | 4.216 | 0.121 | 0.019 | 0.991 | 2.934 | 0.231 |

* $P < 0.05$
gene promoter. Higher basal expression of FasL is significantly associated with FasL −844C allele compared with FasL −844T allele. The C allele and its flanking sequence constitute CAAT box which is the binding site for CAAT Enhancer Binding Protein Beta (C/EBPb), resulting in a significantly higher basal FasL expression [16, 18]. FasL −844T/C polymorphism may influence FasL expression level and FasL-mediated signaling pathway, and ultimately, the susceptibility to cancer.

Fas–FasL system involves in immune escape with two kinds of mechanisms: FasL on tumor cells cross-links with Fas on tumor-infiltration lymphocyte (TIL) to induce TIL apoptosis [19–22]. Meanwhile, TIL in tumor microenvironment can kill each other through AICD by Fas–FasL pathway [23, 24]. Fas can regulate apoptosis effect of FasL. In our study, both FasL −844T/C and Fas −1377G/A polymorphisms were associated with the susceptibility of pulmonary AD. However, only when FasL −844 genotype was CC, Fas −1377 GG was a risk factor for lung AD, and Fas −1377 genotypes showed significant effect modification of pulmonary AD risk by FasL −844 genotype, which is consistent with the mechanism.

Sung et al. studied the association of FasL −844CC SNPs with NSCLC in Taiwan [25]. They found that the FasL −844T/C genotype was not associated with lung cancer risk in case–control study. Ter-Minassian et al. studied the association of these SNPs with NSCLC in a large case–control study in Canada [26]. No associations with NSCLC were observed in the main effects analysis for FasL −844C/T and Fas −1377G/A adjusting for age, gender, smoking status, pack-years, and years since smoking cessation. In subjects under age 60, for FasL −844C/T polymorphism, CT compared with the CC genotype was significantly associated with increased risk of NSCLC. Zhang et al. examined the contribution of these polymorphisms to risk of developing lung cancer in northern China [27]. Compared with noncarriers, there was a 1.59-fold excess risk of developing lung cancer for carriers of the Fas −1377AA genotype and 1.79-fold excess risk for carriers of FasL −844CC. Fas and FasL genotypes were determined in 582 lung cancer patients and 582 healthy control subjects who were frequency-matched for age and gender in Korea [28]. Both genotypes and Fas haplotypes exhibited no apparent relationship with the risk of lung cancer. In addition, there was no significant interaction between Fas and FasL polymorphisms in the development of lung cancer. The results suggested that Fas −1377G/A and −670A/G and FasL −844T/C polymorphisms did not significantly affect the susceptibility to lung cancer in Koreans.

We investigated the association between FasL −844T/C and Fas −1377 polymorphism on the risk of pulmonary AD in South China population. In this study, FasL −844 and Fas −1377 genotypes were risk factors for pulmonary AD. Furthermore, FASL −844CC and Fas −1377GG were risk factors for pulmonary AD by genotypes analyses. These two genotypes were risk factors for patients <60 years old and did not increase the risk of disease in patients ≥60, suggesting that patients <60 years old had strong immune function and immune suppression may increase the risk of cancer, while being ≥60 with weak immune function suffering a certain degree of immuno-suppression did not increase the risk of cancer. Fas −1377, only in the present of FasL −844CC genotype, could increase the risk of cancer. Fas −1377 genotypes showed significant effect modification of pulmonary AD risk by FasL −844 genotype by test of the interaction term adjusting for age, gender, FasL −844, and Fas −1377 SNP. This result verifies the mechanism of Fas–FasL-mediated cell apoptosis: FasL can induce cell apoptosis by cross-linking with Fas.

It had been shown that Fas expression did not correlate with age, sex, histological type, or stage of disease. However, NSCLC expressing FasL was associated with poor clinical prognosis and metastasis [25]. Sung et al. found that the FasL −844CC genotype had higher prevalence in those with advanced tumors than in those with early tumors. Not only did we find that FasL −844CC is associated with stage of pulmonary AD but also we found that this genotype is the risk factor for lymph node metastasis, especially in patients for age equal and over 60 years. So, pulmonary AD cells with FasL −844CC may have strong invasiveness.

Conclusions

In conclusion, FasL −844 and Fas −1377 genotypes were risk factors for pulmonary AD for patients <60 old. Fas −1377, only in the present of FasL −844CC genotype, could increase the risk of cancer. Fas −1377 genotypes showed significant effect modification of pulmonary AD risk by FasL −844 genotype by test of the interaction term. FasL −844CC was a risk factor for tumor stage and lymph node metastasis. Therefore, FasL −844 genotype plays an important role in the occurrence and progression of pulmonary AD.

Acknowledgments This work was supported by the Natural Science Foundation of Zhejiang (LY14H160013) and General Research Project of Zhejiang Medical College (2013XZB02).

Conflicts of interest None

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69–90.
2. Devesa SS, Bray F, Vizcaino AP, et al. International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer. 2005;117(2):294–9.

3. Morita T. A statistical study of lung cancer in the annual of pathological autopsy cases in Japan, from 1958 to 1997, with reference to time trends of lung cancer in the world. Jpn J Cancer Res. 2002;93(1):15–23.

4. Risch A, Plass C. Lung cancer epigenesist and genetics. Int J Cancer. 2008;123(1):1–7.

5. Cho WC. Cancer research on non-small cell lung cancer in smokers and non-smokers: snapshots from the AACR annual meeting 2009. Cancer Biol Ther. 2009;8(14):1309–12.

6. Fan XQ, Guo YJ. Apoptosis in oncology. Cell Res. 2001;11(6835):1–7.

7. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342–8.

8. Nagata S, Golstein P. The Fas death factor. Science (Wash DC). 1996;267:1449–56.

9. Griffith TS, Ferguson TA. The role of FasL-induced apoptosis in immune privilege. Immunol Today. 1997;18:240–4.

10. Houston A, O’Connell J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr Opin Pharmacol. 2004;4:321–6.

11. Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes Fas and FasL in esophageal squamous-cell carcinoma. J Natl Cancer Inst. 2004;96:1030–6.

12. Tian J, Pan F, Li J, et al. Association between the Fas/FasL polymorphisms and gastric cancer risk: a meta-analysis. Asian Pac J Cancer Prev. 2012;13:945–51.

13. Gormus U, Ergen A, Yilmaz H, et al. Fas –1377A/G and FasL T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res. 2007;27:991–4.

14. Lai HC, Lin WY, Lin YW, et al. Genetic polymorphisms of Fas/FasL (CD95/CD95L) genes in cervical carcinogenesis: an analysis of haplotype and gene–gene interaction. Gynecol Oncol. 2005;99:113–8.

15. Li C, Wu W, Liu J, et al. Functional polymorphisms in the promoter regions of the Fas and Fas ligand genes and risk of bladder cancer in south China. Pharmacogenet Genomics. 2006;16:245–51.

16. Zhao H, Zheng L, Li X, et al. FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance. Sci Rep. 2014;4:3866–74.

17. Yao R, Wang Y, Lubet RA, et al. Differentially expressed genes associated with mouse lung tumor progression. Oncogene. 2002;21(37):5814–21.

18. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol. 2003;170(1):132–8.

19. Bennett MW, O’connell J, O’Sullivan GC, et al. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut. 1999;44:156–62.

20. Huber V, Fais S, Iero M, et al. Human colorectal cancer cells induce T-cell death through release of proapoptotic microvesicles: role in immune escape. Gastroenterology. 2005;128:1796–804.

21. Minas V, Rolaki A, Kalantaridou SN, et al. Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. Br J Cancer. 2007;97:637–45.

22. O’Connell J, O’Sullivan GC, Collins JK, et al. Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075–82.

23. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol. 2002;80:131–7.

24. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother. 1998;47:65–71.

25. Sung WW, Wang YC, Cheng YW, et al. A polymorphic -844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res. 2011;17(18):5991–9.

26. Ter-Minassian M, Zhai R, Asomaning K, et al. Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis. 2008;29(11):2147–52.

27. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes Fas and FasL contribute to risk of lung cancer. J Med Genet. 2005;42(6):479–84.

28. Park SH, Choi JE, Kim EJ, et al. Polymorphisms in the Fas and FasL genes and risk of lung cancer in a Korean population. Lung Cancer. 2006;54(3):303–8.